(EW) Edwards Lifesciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US28176E1082

Valves, Heart, Transcatheter, Replacement

EW EPS (Earnings per Share)

EPS (Earnings per Share) of EW over the last years for every Quarter: "2020-03": 0.49, "2020-06": -0.2, "2020-09": 0.52, "2020-12": 0.49, "2021-03": 0.54, "2021-06": 0.78, "2021-09": 0.54, "2021-12": 0.53, "2022-03": 0.59, "2022-06": 0.65, "2022-09": 0.55, "2022-12": 0.65, "2023-03": 0.56, "2023-06": 0.5, "2023-09": 0.63, "2023-12": 0.61, "2024-03": 0.58, "2024-06": 0.61, "2024-09": 5.13, "2024-12": 0.65, "2025-03": 0.61,

EW Revenue

Revenue of EW over the last years for every Quarter: 2020-03: 1128.7, 2020-06: 925, 2020-09: 1140.9, 2020-12: 1191.7, 2021-03: 1216.6, 2021-06: 1376, 2021-09: 1310.2, 2021-12: 1329.7, 2022-03: 1341.2, 2022-06: 1373.9, 2022-09: 1319, 2022-12: 1348.3, 2023-03: 1459.6, 2023-06: 1530.2, 2023-09: 1480.9, 2023-12: 1534.1, 2024-03: 1598.2, 2024-06: 1385.9, 2024-09: 1354.4, 2024-12: 1385.8, 2025-03: 1412.7,

Description: EW Edwards Lifesciences

Edwards Lifesciences Corporation is a leading global provider of innovative cardiovascular solutions, offering a range of products and technologies to treat advanced cardiovascular diseases. The companys transcatheter heart valve replacement products, including the Edwards SAPIEN family of valves, have revolutionized the treatment of aortic heart valves, while its transcatheter heart valve repair and replacement products, such as PASCAL PRECISION and Cardioband, address mitral and tricuspid valve diseases. Additionally, Edwards Lifesciences offers surgical structural heart solutions, including the INSPIRIS and MITRIS RESILIA valves, which feature advanced technologies like RESILIA tissue and VFit.

With a strong presence in the US, Europe, Japan, and internationally, Edwards Lifesciences distributes its products through a combination of direct sales forces and independent distributors. The companys commitment to innovation and quality has enabled it to establish a leadership position in the cardiovascular market. As a result, Edwards Lifesciences has built a reputation for delivering high-quality products that improve patient outcomes and drive growth.

Analyzing the , we observe that the stock has been trending upwards, with the short-term and long-term moving averages (SMA20, SMA50, and SMA200) indicating a bullish sentiment. The Average True Range (ATR) suggests moderate volatility. Considering the , Edwards Lifesciences market capitalization and Return on Equity (RoE) indicate a strong financial position. The Price-to-Earnings (P/E) ratio and Forward P/E suggest that the stock is reasonably valued relative to its earnings growth.

Based on the and , our forecast suggests that Edwards Lifesciences Corp (NYSE:EW) is poised for continued growth, driven by its innovative product pipeline and strong financial position. We anticipate that the stock will continue to trend upwards, potentially reaching the 52-week high of $93.78 or higher, as the companys transcatheter heart valve replacement products and surgical structural heart solutions continue to gain traction in the market. However, investors should be aware of the moderate volatility indicated by the ATR and adjust their strategies accordingly.

Additional Sources for EW Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

EW Stock Overview

Market Cap in USD 45,045m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2000-03-27

EW Stock Ratings

Growth Rating -1.78
Fundamental 43.1
Dividend Rating 0.0
Rel. Strength -12.6
Analysts 3.69 of 5
Fair Price Momentum 71.57 USD
Fair Price DCF 20.90 USD

EW Dividends

Currently no dividends paid

EW Growth Ratios

Growth Correlation 3m 61.8%
Growth Correlation 12m 52.3%
Growth Correlation 5y -53.4%
CAGR 5y 2.41%
CAGR/Max DD 5y 0.04
Sharpe Ratio 12m -0.53
Alpha -25.48
Beta 0.500
Volatility 28.34%
Current Volume 2412k
Average Volume 20d 3090.8k
Stop Loss 73.7 (-3.5%)
What is the price of EW shares?
As of July 09, 2025, the stock is trading at USD 76.39 with a total of 2,411,983 shares traded.
Over the past week, the price has changed by -1.02%, over one month by +0.04%, over three months by +13.90% and over the past year by -16.82%.
Is Edwards Lifesciences a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, Edwards Lifesciences (NYSE:EW) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 43.11 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EW is around 71.57 USD . This means that EW is currently overvalued and has a potential downside of -6.31%.
Is EW a buy, sell or hold?
Edwards Lifesciences has received a consensus analysts rating of 3.69. Therefor, it is recommend to hold EW.
  • Strong Buy: 10
  • Buy: 4
  • Hold: 17
  • Sell: 0
  • Strong Sell: 1
What are the forecasts for EW share price target?
According to our own proprietary Forecast Model, EW Edwards Lifesciences will be worth about 80.3 in July 2026. The stock is currently trading at 76.39. This means that the stock has a potential upside of +5.13%.
Issuer Target Up/Down from current
Wallstreet Target Price 81 6%
Analysts Target Price 80.9 5.9%
ValueRay Target Price 80.3 5.1%